Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


ASCO GU 2017: KEYNOTE-052

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews.

Speaker: Arjun Balar

Poster: B284 - Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items